Key result
Selective PKC-ε inhibition reverses LPS-induced peak INa reduction and cellular arrhythmias in Brugada syndrome models.
Why the study?
Fever and inflammation can exacerbate the Brugada syndrome (BrS) phenotype, but the underlying pathogenic mechanisms and the potential role of protein kinase C (PKC) were not clarified.
Does lipopolysaccharide exacerbate the Brugada syndrome phenotype via protein kinase C epsilon (PKC-ε) activation in SCN5A-mutant hiPSC-derived cardiomyocytes?
Does lipopolysaccharide exacerbate the Brugada syndrome phenotype via protein kinase C epsilon (PKC-ε) activation in SCN5A-mutant hiPSC-derived cardiomyocytes?
In a human iPSC-derived cardiomyocyte model of Brugada syndrome with an SCN5A variant, inflammation induced by lipopolysaccharide exacerbates sodium channel dysfunction and cellular arrhythmias specifically through PKC-ε activation.
Inflammasome inhibition may blunt LPS-triggered arrhythmias in SCN5A-mutant BrS cardiomyocytes; leaves open whether PKC or inflammasome targeting merits clinical study.
Background Fever and inflammation can exacerbate the phenotype of Brugada syndrome (BrS). However, the underlying mechanisms of fever or inflammation in the pathogenesis of BrS are not clarified. This study aimed to study the potential roles of protein kinase C (PKC) in the effects of inflammation on the phenotype of BrS. Method The human induced pluripotent stem cell (hiPSC) lines were generated from fibroblasts of a BrS patient harboring a mutation (c.3148G>A, p.Ala1050Thr) in SCN5A, as well as from a healthy donor and a site-corrected (using CRISPR/Cas9) cell line. Western blot, qPCR, and patch clamp analyses were carried out. Result Lipopolysaccharide (LPS, 2 µg/ml 24 h) reduced peak INa and increased the number of cells displaying arrhythmic events in BrS-hiPSC-CMs but not in healthy donor-hiPSC-CMs, implying that LPS can exacerbate the BrS phenotype. Bisindolylmaleimide I (10 µM), a PKC α/β inhibitor, showed no impact on the LPS effect on peak INa, but Enzastaurin (10 µM), a PKC α/β/ε inhibitor, reversed the LPS effect on INa. Additionally, C2V1 (10 µM), a selective inhibitor of PKC-ε, reversed the LPS effect on INa. A selective PKC-ε activator, RACK (10 µM), could inhibit INa. These data suggest that PKC-ε but not PKC α/β mediated the reduction of INa caused by LPS challenge. Further study showed that LPS increased the expression level of PKC-α in healthy donor-hiPSC-CMs and isogenic cells, but not in BrS-hiPSC-CMs. PKC β/ε expression significantly increased in BrS-hiPSC-CMs. These data may suggest a dissociation between PKC isoform upregulation and sodium channel dysfunction, with PKC ε acting as a dominant effector. Conclusion LPS can exacerbate BrS phenotype through activating PKC-ε. LPS induced a dissociation between PKC isoform upregulation and functional sodium channel regulation.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied Brugada syndrome (BrS) with SCN5A variant (c.3148G>A, p.Ala1050Thr). Lipopolysaccharide (LPS) and PKC modulators (Bisindolylmaleimide I, Enzastaurin, C2V1, RACK) vs. Healthy donor-hiPSC-CMs and CRISPR/Cas9 site-corrected isogenic cell line was evaluated on Peak sodium current (INa) and cellular arrhythmic events. Lipopolysaccharide (2 µg/ml for 24 h) reduced peak INa and increased arrhythmic events in BrS-hiPSC-CMs, an effect reversed by selective PKC-ε inhibition with C2V1 (10 µM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: